Author Archives: Ryan Adsit

Stifel Nicolaus Reaffirms Their Buy Rating on Inventiva (IVA)

In a report issued on January 4, Derek Archila from Stifel Nicolaus maintained a Buy rating on Inventiva (IVA – Research Report), with a price target of $18.00. The company’s shares closed last Wednesday at $19.00. According to TipRanks.com, Archila

Raymond James Remains a Buy on Alimentation Couche Tard (ANCUF)

Raymond James analyst Bobby Griffin maintained a Buy rating on Alimentation Couche Tard (ANCUF – Research Report) on November 5. The company’s shares closed last Tuesday at $29.51. According to TipRanks.com, Griffin is a 5-star analyst with an average return

Analysts Are Bullish on These Healthcare Stocks: Zynerba Pharmaceuticals (ZYNE), Beyondspring (BYSI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals (ZYNE – Research Report) and Beyondspring (BYSI – Research Report) with bullish sentiments. Zynerba Pharmaceuticals (ZYNE) In a report issued

Canaccord Genuity Keeps Their Buy Rating on Enthusiast Gaming Holdings (ENGMF)

In a report released yesterday, Robert Young from Canaccord Genuity maintained a Buy rating on Enthusiast Gaming Holdings (ENGMF – Research Report), with a price target of C$7.50. The company’s shares closed last Friday at $4.25, close to its 52-week

Cardiff Oncology (CRDF) Receives a Rating Update from a Top Analyst

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cardiff Oncology (CRDF – Research Report) today and set a price target of $27.00. The company’s shares closed last Friday at $13.46. According to TipRanks.com, Selvaraju is a top 100

H.C. Wainwright Sticks to Its Buy Rating for Meridian Bioscience (VIVO)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Meridian Bioscience (VIVO – Research Report) today and set a price target of $30.00. The company’s shares closed last Friday at $21.59. According to TipRanks.com, Chen is a top 100